肺癌免疫治疗标志物研究进展认识

doi:10.16150/j.1671-2870.2018.05.003

诊断学理论与实践 ›› 2018, Vol. 17 ›› Issue (05): 494-498.doi: 10.16150/j.1671-2870.2018.05.003

肺癌免疫治疗标志物研究进展认识

王晓斐¹, 高蓓莉¹

上海交通大学医学院附属瑞金医院呼吸与危重症医学科,上海 200025

收稿日期:2018-09-12 出版日期:2018-10-25 发布日期:2018-10-25
通讯作者: 高蓓莉 E-mail: yshu7661@sina.com
基金资助:
国家自然科学基金（81702250）

Received:2018-09-12 Online:2018-10-25 Published:2018-10-25

摘要/Abstract

关键词: 免疫治疗, 肺癌, 程序性死亡受体1, 肿瘤突变负荷

中图分类号:

R734.2

王晓斐, 高蓓莉. 肺癌免疫治疗标志物研究进展认识[J]. 诊断学理论与实践, 2018, 17(05): 494-498.

[1] Chen DS, Irving BA, Hodi FS.Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1[J]. Clin Cancer Res,2012,18(24):6580-6587.
[2] Patel SP, Kurzrock R.PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy[J]. Mol Cancer Ther,2015,14(4):847-856.
[3] Reck M, Rodríguez-Abreu D, Robinson AG, et al.Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer[J]. N Engl J Med,2016,375(19):1823-1833.
[4] Hirsch FR, McElhinny A, Stanforth D, et al. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project[J]. J Thorac Oncol,2017,12(2):208-222.
[5] Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer[J]. Science.2015 Apr 3;348(6230):124-128.
[6] Goodman AM, Kato S, Bazhenova L, et al.Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers[J]. Mol Cancer Ther,2017,16(11):2598-2608.
[7] Carbone DP, Reck M, Paz-Ares L, et al.First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer[J]. N Engl J Med,2017,376(25):2415-2426.
[8] Antonia SJ, López-Martin JA, Bendell J, et al.Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial[J]. Lancet Oncol,2016,17(7):883-895.
[9] Hellmann MD, Ciuleanu TE, Pluzanski A, et al.Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden[J]. N Engl J Med,2018,378(22):2093-2104.
[10] Ilson DH.Nivolumab for Metastatic MSI-High/dMMR Colorectal Cancer[J]. NEJM Journal Watch,2017.
[11] Sclafani F.PD-1 inhibition in metastatic dMMR/MSI-H colorectal cancer[J]. Lancet Oncol,2017,18(9):1141-1142.
[12] Quiroga D, Lyerly HK, Morse MA.Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer[J]. Curr Treat Options Oncol,2016,17(8):41.
[13] Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study[J]. Lancet Oncol,2017,18(9):1182-1191.
[14] Mehnert JM, Panda A, Zhong H, et al.Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer[J]. J Clin Invest,2016,126(6):2334-2340.
[15] Dong ZY, Zhong WZ, Zhang XC, et al.Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma[J]. Clin Cancer Res,2017,23(12):3012-3024.
[16] Gainor JF, Shaw AT, Sequist LV, et al.EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis[J]. Clin Cancer Res,2016,22(18):4585-4593.
[17] Shin DS, Zaretsky JM, Escuin-Ordinas H, et al.Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations[J]. Cancer Discov,2017,7(2):188-201.
[18] Wezel F, Vallo S, Roghmann F, et al.Do we have biomarkers to predict response to neoadjuvant and adjuvant chemotherapy and immunotherapy in bladder cancer?[J]. Transl Androl Urol,2017,6(6):1067-1080.
[19] Kato S, Goodman A, Walavalkar V, et al.Hyperprogressors after Immunotherapy: Analysis of Genomic Altera-tions Associated with Accelerated Growth Rate[J]. Clin Cancer Res,2017,23(15):4242-4250.
[20] Sivan A, Corrales L, Hubert N, et al.Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy[J]. Science,2015,350(6264):1084-1089.
[21] Routy B, Le Chatelier E, Derosa L, et al.Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors[J]. Science,2018,359(6371):91-97.

肺癌免疫治疗标志物研究进展认识

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	孙艳艳, 兰信堂. 肺癌颅脑转移患者接受放射治疗后前庭功能受损1例[J]. 诊断学理论与实践, 2022, 21(05): 632-634.
[2]	罗雅方, 徐倩玥, 余红. 尘螨在特应性皮炎中的致病机制及相关免疫治疗应用研究进展[J]. 诊断学理论与实践, 2021, 20(06): 592-595.
[3]	苏长青. 从基础研究到临床转化应用谈肝癌的诊治进展[J]. 诊断学理论与实践, 2021, 20(05): 427-433.
[4]	周艺, 杨莉. 粒细胞-巨噬细胞集落刺激因子在肿瘤免疫治疗中的作用机制及临床应用进展[J]. 诊断学理论与实践, 2021, 20(04): 407-413.
[5]	吴歆, 耿旭强, 徐沪济. 多基因风险评分在复杂性状疾病中的应用进展[J]. 诊断学理论与实践, 2020, 19(05): 540-543.
[6]	杜海磊, 陈聆, 罗方秀, 李勇, 程齐俭, 朱良纲, 杭钧彪. Beclin-1和Bcl-2表达与非小细胞肺癌患者病理特征及预后间关系的研究[J]. 诊断学理论与实践, 2020, 19(03): 258-263.
[7]	王晓妍, 潘丽娜, 高蓓莉, 徐志红, 胡家安. 影像组学及影像基因组学在肺癌诊疗中的应用进展[J]. 诊断学理论与实践, 2019, 18(06): 711-714.
[8]	刘海霞, 瞿介明. 肺部微生态及其与肺癌关系的研究进展[J]. 诊断学理论与实践, 2019, 18(05): 496-502.
[9]	罗清琼, 陈福祥. 肿瘤免疫治疗策略的转变及相关标志物研究现状[J]. 诊断学理论与实践, 2019, 18(04): 387-393.
[10]	张新, 张新宇. 支气管冲洗液基因检测在肺癌诊治中的价值[J]. 诊断学理论与实践, 2018, 17(05): 508-511.
[11]	张国桢, 蔡庆, 张伟强. 早期微小肺腺癌CT影像与病理的相关性[J]. 诊断学理论与实践, 2018, 17(05): 490-493.
[12]	顾圣佳, 曹琪琪, 严福华, 杨文洁. 双能CT在非小细胞肺癌非手术治疗疗效评估中的应用价值[J]. 诊断学理论与实践, 2018, 17(05): 526-532.
[13]	韩宝惠, 沈胤晨. 我国肺癌筛查现状与展望[J]. 诊断学理论与实践, 2018, 17(05): 487-489.
[14]	马韵芳, 潘丽娜, 张培培, 何清, 徐志红, 胡家安. 人类表皮生长因子受体2基因扩增的非小细胞肺癌一例报告[J]. 诊断学理论与实践, 2018, 17(04): 462-465.
[15]	娄加陶, 张宸梓. 外泌体的检测及临床应用[J]. 诊断学理论与实践, 2018, 17(02): 141-146.